Cloud Of Uncertainty Has Been Covering Gilead Over The Past Year But That's Not Bad

Biotech stocks have been doing relatively well in the past week as depicted by the iShares NASDAQ Biotechnology ETF increasing to the tune of 3.5% but shares of Gilead have not echoed that move upwards. If we even broaden our view of the ETF versus Gilead to the past year, we see that Gilead is down 0.7% while the IBB is up 11.9%.

from Biotech News